We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Estrogen Hormone Protocol

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000177
First Posted: November 1, 1999
Last Update Posted: December 11, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Aging (NIA)
  Purpose
Estrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because this hormone also has many beneficial effects on brain cells, it currently is being studied as a treatment for Alzheimer's disease. The enzyme that forms the neurotransmitter acetylcholine is promoted in the presence of estrogen. Several very small clinical studies have demonstrated improvement in cognitive function and mood measures in women with Alzheimer's disease who take estrogen.

Condition Intervention Phase
Alzheimer Disease Drug: Estrogen Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Institute on Aging (NIA):

Estimated Enrollment: 120
Study Start Date: October 1995
Study Completion Date: January 1999
Primary Completion Date: January 1999 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women with a diagnosis of Alzheimer's disease who currently are not taking estrogen replacement therapy, who have had a hysterectomy, and who are in stable general health.

Exclusion Criteria:

  • Patients with an uncontrolled health problem, such as untreated high blood pressure or thyroid disease.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000177


  Show 25 Study Locations
Sponsors and Collaborators
National Institute on Aging (NIA)
Investigators
Principal Investigator: Leon Thal, MD. University of California, San Diego
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00000177     History of Changes
Other Study ID Numbers: IA0001
3U01AG010483-08S2 ( U.S. NIH Grant/Contract )
First Submitted: October 29, 1999
First Posted: November 1, 1999
Last Update Posted: December 11, 2009
Last Verified: September 2009

Keywords provided by National Institute on Aging (NIA):
Alzheimer's disease
Estrogen

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs